3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
96
Stomach Neoplasms
53
Rectal Neoplasms
49
Pancreatic Neoplasms
42
Colonic Neoplasms
34
Esophageal Neoplasms
30
Neoplasm Metastasis
28
Neoplasms
23
Adenocarcinoma Of Esophagus
19
Adenocarcinoma
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Lymphoma, Large B-Cell, Diffuse
7
Gallbladder Neoplasms
7
Biliary Tract Neoplasms
7
Esophageal Squamous Cell Carcinoma
6
Carcinoma, Non-Small-Cell Lung
6
Ovarian Neoplasms
5
Liver Neoplasms
5
Head and Neck Neoplasms
5
Cholangiocarcinoma
5
Recurrence
4
Lymphoma, Non-Hodgkin
4
Gastrointestinal Neoplasms
4
Carcinoma, Hepatocellular
4
Breast Neoplasms
4
Bile Duct Neoplasms
4
Peritoneal Neoplasms
3
Pancreatic Adenocarcinoma
3
Leukemia
3
Fallopian Tube Neoplasms
3
Interventions
pembrolizumab
3
Nivolumab
2
vicriviroc
1
spartalizumab
1
relatlimab
1
copanlisib
1
binimetinib
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Spinocerebellar Degenerations
×
Oxaliplatin
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts